Application Rec'd	Human Subjects Rec'd	Reviewed & Approved	Added to Dea List	Guidelines Sent	Natworked:
Application Rec u	Truman Subjects Ree u	Reviewed & Approved	Added to Key. List		NCIWOIKCU .


### APPLICATION: COOPERATIVE HUMAN TISSUE NETWORK

- **I. DIRECTIONS** This application is intended for the use and processing of samples utilized by the laboratory and/or personnel that fall under the supervision of the PI listed in the application. Any transfer of samples or aliquots to personnel or laboratories that are not under the supervision of the indicated PI requires the following:
  - An explanation of the need to transfer the materials and benefit to the investigator's research
  - A copy of the enclosed CHTN agreement page signed by the collaborator
  - A copy of the collaborator's IRB approval unless the collaborator is covered under the IRB approval granted for the project proposed in this application

The CHTN does not supply samples to banks solely for distribution to third party researchers; those researchers should be encouraged to apply to the CHTN directly.

The information requested in these forms is necessary in order to document correctly your request for tissue and other services and to ensure that the CHTN operates within the guidelines of the National Cancer Institute. When submitting a written request for services:

- A. Please print neatly or type.
- B. Please be specific about your requirements for handling tissue samples from the time the specimen is collected until it is delivered to your lab (i.e., need for sterility, transport media, refrigeration status, etc.).
- C. Patient identity is confidential. Samples will be coded and delivered at a processing fee of \$20/sample for researchers at academic institutions and \$60/sample for researchers at non-academic institutions, plus shipping costs. Additional charges may be assessed for special preparation.
- D. Investigators must have human use approval to receive tissue from the CHTN. Either full or expedited approval can be obtained from your Institutional Review Board (Human Use Committee). A COPY OF THE HUMAN SUBJECTS APPROVAL SHOULD BE ATTACHED TO THIS FORM. An annual human subjects review is required and must be forwarded to the CHTN in order to maintain your eligibility to receive tissue.
- E. For pediatric tissue (available nationwide) please complete this application and mail directly to Children's Hospital at the address shown below.
- F. For additional information call the Division for your state (see map below). Send completed forms to this division.



#### EASTERN DIVISION

University of Pennsylvania Med. Center 3400 Spruce Street 566 Dulles Philadelphia, PA 19104-4283 215-662-4570 215-614-0251 (FAX) chtneast@mail.med.upenn.edu

#### PEDIATRIC DIVISION

Columbus Children's Hospital 700 Children's Drive Room W135 Columbus, OH 43205 614-722-2714 614-722-2897 (FAX) BrewerS@pediatrics.ohio-state.edu

#### MID-ATLANTIC DIVISION

University of Virginia CHTN-Department of Pathology P.O. Box 800423 Charlottesville, VA 22906 434-924-9879 434-924-9438 (FAX) uva-chtn@virginia.edu

#### SOUTHERN DIVISION

Tissue Procurement, ZRB 449 University of Alabama at Birmingham 1530 Third Ave. South Birmingham, AL 35294-0007 205-934-6071 205-934-0816 (FAX) sexton@path.uab.edu

#### MIDWESTERN DIVISION

The Ohio State University
Tissue Procurement, M376 Starling Loving Hall
320 W. 10<sup>th</sup> Avenue
Columbus, OH 43210
614-293-5493
614-293-5851 (FAX)
Johnson-60@medctr.osu.edu

#### WESTERN DIVISION

Vanderbilt University Medical Center 4918 TVC Boulevard 22<sup>nd</sup> & Pierce Avenue Nashville, TN 37232-5310 615-936-2873 615-322-4741 (FAX) kerry.wiles@vanderbilt.edu

# II. INVESTIGATOR DATA A. Principal Investigator: Last Name First Name Middle Initial Degree Investigator's Title: Primary Mailing Address (Street/Bldg./Room#): Institution: \_\_\_\_\_ State:\_\_\_\_\_ Zip:\_\_\_\_ City:\_\_\_\_ Phone (Day):\_\_\_\_\_\_(Nights/Weekends):\_\_\_\_\_ \_\_e-mail FAX Number at which you may be notified: Contact Person: Lab/Phone: e-mail Shipping Address (*if different from above*): B. Department: Street/Bldg./Room#: City:\_\_\_\_\_\_ State:\_\_\_\_ Zip: \_\_\_\_\_ C. Billing Information: Is a purchase order required for shipment of specimens to your institution? Yes \_\_\_\_ No\_\_\_\_ If so, please list name of contact for P.O.: Phone: Currently invoices are included with the tissue shipment to the shipping address listed in section B. If you would like the original invoice to be mailed to another location (eg. your billing department), please enter that address below. A copy of the invoice will also be included with your shipment. Billing Address (if different from the shipping address): Department: Street/Bldg./Room#: \_\_\_\_\_ State: \_\_\_\_ Zip: (Shipping charges will be added to your invoice unless you provide a Federal Express number.) Federal Express Number **FUNDING INFORMATION** Tissues will be provided to investigators on a rotating basis in the following priority order:

#### III.

- 1. Peer reviewed funded investigators (including Federal and National laboratories)
- 2. New investigators and academic investigators developing new research projects.
- 3. Other investigators
- To help determine your priority, please include your major research grant. Institutional and other funding sources may be A. listed. If you are currently unfunded, please indicate below:

**Funding Source** 

Period of Support

Please provide the title and a short research summary of the proposed research on the tissues you are requesting from the В. CHTN (use separate page).

IV.	SER	VICES REQUESTED (Please c	copy this page as needed for multiple requests.)						
	A.	Human Tissue Specimen Crite	eria						
		1. Anatomic Site or Tiss	sue Type:						
		Malignant;	_Benign;Normal;Diseased;Other:						
			please specify: Primary and/or mets; Primary only; Mets only lignant OR specify type of malignancy:						
available		ssue from the same patient <u>required</u> ? Yes; No; If							
		3. Will you accept tissue	e from patients previously treated with: Radiation; Chemotherapy						
		4. Must specimen be ster	Must specimen be sterile?Yes; No; As clean as possible						
		5. Gender: Male	Gender: Male Female Either						
		6. Tissue Source:							
		•	Must be frozen withinhrs of sx ORtime constraint not applicable						
		• •	: Must be collected within hours after death						
		7. Patient Limitations (i.e.	.e., age, race, or other limiting characteristics):						
		8. Amount of tissue requ	uired (minimum to maximum size or dimension):						
	eeded:								
			ples needed:						
		11. Requested starting dat	ate to receive tissue:						
	B.	Preparation and Preservation of Samples (please mark only those that apply)							
	Fresh. Indicate media	a requirements:							
		Transport Media	ia; Saline; Dry; Other:						
		(if preference for transport media, e.g. RPMI, L-15, DMEM, please indicate):							
		Wrap in Gauze?Yes No							
		Add supplements:							
		Antibiotics	S (indicate type & amount)						
		Fetal Calf S	Serum (indicate percentage)						
	Fungizone	e (indicate amount)							
	Shipping Requirements (wet ice, room temp. etc. )								
	<b>Frozen.</b> Indicate freezing requirements (fresh-frozen, OCT, etc.):								
	<b>Fixed</b> . Indicate fixative requirements (10% BNF, etc.):								
		Will you accept Saturday delive	veries, if notified? Yes; No; Sometimes, if notified						
	C.	control diagnosis and patient a patient information may be a	: (Anatomic site of tissue, provisional diagnosis, final diagnosis, quality age, sex and race [if available] will be provided for all samples.) Additiona available, but you must request it in this application and justify its Requests for additional information cannot be accepted after the						

(NOTE: please notify your division coordinator ASAP if your needs change).

## **AGREEMENT**

The recipient hereby agrees: that the tissues to be provided by the Cooperative Human Tissue Network will be used only for the research purposes specified in this application; that no attempt will be made to learn the identity or other information about the subjects providing tissue; and that tissues and their directly extracted products shall not be sold (or distributed free of charge) to third parties, nor as commercial products; specifically aliquots of tissues provided by the CHTN or extracts from these tissues (e.g., protein, mRNA or DNA) shall not be distributed to third parties or marketed commercially.

We understand that while the CHTN attempts to avoid supplying tissues contaminated with highly infectious agents such as hepatitis and HIV, all tissues should be handled as if potentially infectious. Permission from patients to clinically test their tissues (e.g., for the presence of infective agents such as hepatitis) has not been obtained and such testing shall not be performed on the tissues supplied by the CHTN. If clinical information is obtained in the course of the study that is deemed by the principal investigator of the study to be important to the care of the patient who is the source of this tissue, the investigator shall request permission from his/her local IRB before contacting the CHTN regarding this information. The recipient acknowledges that he/she is aware of and follows OSHA regulations for handling human specimens and will instruct their staff to abide by those rules. The recipient further agrees to assume all responsibility for informing and training personnel in the dangers and procedures for safe handling of human tissues.

Tissues are provided as a service to the research community without warranty of merchantability or fitness for a particular purpose or any other warranty, express or implied. The CHTN accepts no responsibility for any injury (including death), damages or loss that may arise either directly or indirectly from their use.

The recipient hereby agrees to acknowledge the contributions of the Cooperative Human Tissue Network in all publications resulting from the use of these tissues. Recommended wording to the methods or acknowledgment section is as follows: Tissue samples were provided by the Cooperative Human Tissue Network, which is funded by the National Cancer Institute. Other investigators may have received specimens from the same subjects.

**FOR STATE INSTITUTIONS:** The recipient institution agrees to be responsible for any claims, costs, damages, or expenses resulting from any injury (including death), damage or loss that may arise solely from the receipt, handling, storage and use of tissues received from the CHTN to the extent permitted under the laws of this State. The undersigned warrant that they have authority to execute this agreement on behalf of the recipient institution.

**FOR U.S. GOVERNMENT AGENCIES**: On behalf of the United States Government, we assume all risks and responsibilities in connection with the receipt, handling, storage and use of tissues received from the Cooperative Human Tissue Network. The United States assumes liability for any claims, damages, injury or expense arising from the use of the material or any derivative, but only to the extent provided under the Federal Tort Claims Act (28 U.S.C. Chap. 171).

**FOR ALL OTHER INSTITUTIONS:** The recipient institution agrees to assume all risks and responsibility in connection with the receipt, handling, storage and use of tissues. It further agrees to indemnify and hold harmless the Cooperative Human Tissue Network and the United States Government from any claims, costs, damages or expenses resulting from the use of the tissues provided by the CHTN. The undersigned warrant that they have authority to execute this agreement on behalf of the recipient institution.

BY MY SIGNATURE I AGREE TO THE TERMS SET FORTH IN THE ABOVE AGREEMENT

Typed Name of Recipient		Agency	Typed Name of Official Authorized to Sign for the Agency		
Signature of Recipient	Date	Division or Department	Authorized Signature Date		

UPON RECEIPT OF THESE SIGNED UNDERSTANDINGS AND THE INFORMATION REQUESTED ABOVE, THE COOPERATIVE HUMAN TISSUE NETWORK WILL CONSIDER THIS REQUEST AND ALL FUTURE REQUESTS FOR TISSUE. Specific questions about your application should be directed to your regional coordinator. Other questions may be directed to the NCI Program Director, Ms. Marianna Bledsoe at 301-496-7147.